MK2-IN-3 (hydrate)

• UNSPSC Description:

  MK2-IN-3 hydrate (compound 16) is an orally active, selective, and ATP-competitive MAPKAP-K2 (MK-2) inhibitor with an IC50 of 0.85 nM.MK2-IN-3 hydrate is exceptional selectivity against MK-3 (IC50=0.21 μM), MK-5 (IC50=0.081 μM), ERK2 (IC50=3.44 μM), MNK1(IC50=5.7 μM) as well as CDK2, JNK2, IKK2, MSK1, and MSK2[1].

• Target Antigen:

  MAPKAPK2 (MK2)

• Type:

  Reference compound

• Related Pathways:

  MAPK/ERK Pathway

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/mk-2-inhibitor-iii.html

• Purity:

  99.0

• Solubility:

  DMSO : 125 mg/mL (ultrasonic)

• Smiles:

  O=C1C2=C(NC(C3=CC(C4=CC5=CC=CC=C5N=C4)=NC=C3)=C2)CCN1.O

• Molecular Weight:

  358.39

• References & Citations:

  [1]Anderson DR, et al. Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2). J Med Chem. 2007 May 31;50(11):2647-54.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  1186648-22-5